Loading clinical trials...
Loading clinical trials...
To investigate the impact of reminders for serum potassium monitoring and of hyperkalemia alerts during potassium-increasing drug-drug-interactions.
The development of hyperkalemia during potassium-increasing drug-drug-interactions (DDIs) is associated with (i) unknown or elevated serum potassium level at onset of treatment and (ii) insufficient monitoring of serum potassium during therapy. However, potassium-increasing DDIs are frequently started despite an unknown or elevated serum potassium level, and monitoring intervals often exceed 48 hours. This study investigates the impact of reminders for serum potassium monitoring and hyperkalemia alerts. Both reminders and alerts are displayed in the electronic patient chart of in-patients treated with potassium-increasing DDIs.
Age
All ages
Sex
ALL
Healthy Volunteers
No
University Hospital Zurich, Center for Clinical Research, Research Center for Medical Informatics
Zurich, Canton of Zurich, Switzerland
Start Date
January 1, 2014
Primary Completion Date
January 1, 2015
Completion Date
January 1, 2015
Last Updated
June 8, 2015
3,341
ACTUAL participants
decision support in potassium-inc. drug-drug-interactions
BEHAVIORAL
Lead Sponsor
University of Zurich
NCT06884267
NCT06366230
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03781089